- Population: Immunocompetent children aged 3–9 months
- Intervention: Two doses of MenA conjugate vaccine (5 µg dosage)
- Comparison: No MenA vaccination
- Outcome: Serogroup A meningococcal disease
What is the scientific evidence concerning the efficacy of two doses of MenA conjugate vaccination (versus no Men A vaccination) against serogroup A meningococcal disease in immunocompetent children aged 3–9 months?
- GRADE table
- Newborn (0-1 years)
- Meningococcal disease